ADHD and Psychosis: Risk, Comorbidity, and Treatment

Dr. Oscar Buckstein, MD

Dr. Bukstein will discuss ADHD as a risk factor for the development of psychotic disorders, patterns of comorbidity, and their treatment.

 Dr. Bukstein is currently Senior Attending Psychiatrist in the Department of Psychiatry and Behavioral Sciences at Boston Children’s Hospital (BCH). and Professor of Psychiatry at Harvard Medical School.

At BCH, Dr. Bukstein has served a Vice-Chair, Director of the Child and Adolescent Psychiatry Fellowship, and Director of Outpatient Services. Prior to coming to Boston Children’s Hospital (BCH) in March 2016, Dr Bukstein spent several years in Houston, Texas at the University of Texas (UT) Health Science Center in Houston where he was Professor of Psychiatry and Chief of the Division of Child and Adolescent Psychiatry and at DePelchin Children’s Center where he was Medical Director. He spent 28 years at the Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh and the University of Pittsburgh School of Medicine.

Dr. Bukstein has over 35 years of practice experience with particular clinical and research expertise in treating youth with substance use disorders, attention deficit hyperactivity disorder, aggressive behavior, and disruptive behavior disorders. Dr. Bukstein has a substantial academic record, having authored or co-authored over 200 papers, chapters, or books or other academic products and has received funding by the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute of Alcohol Abuse and Alcoholism, and the National Institute on Child Health and Human Development.

Register Here: https://us02web.zoom.us/meeting/register/O-BstWkHR6uaSlm0cFllAA

Working with Medical Interpreters: Shifting from Standards of Practice to Intersubjectivity in the Clinical Space

Margaret Lanca
2023 Mass-STEP Conference Day 2

View Slides

Optimal Treatment of Psychotic Disorders: Clozapine, Engagement, and Community

Robert Laitmain, MD & Matcheri Keshavan, MD

Hosted by the New England MHTTC

The program describes a novel approach to engaging patients with psychosis and their families. We seek the development of true collaboration. Critical in this approach is establishing a community of individuals with a common interest that provides support for each other. The support allows the treatment team to secure the patient's trust, develop a therapeutic relationship and do the hard work of creating an optimal clozapine regimen. This session will go on to:

• Describe how we develop clozapine regimens that minimize predictable side effects and optimize benefits;

• Share our results in improving patient outcomes.